Literature DB >> 10850866

Loss of heterozygosity on chromosome 19 in secondary glioblastomas.

M Nakamura1, F Yang, H Fujisawa, Y Yonekawa, P Kleihues, H Ohgaki.   

Abstract

Glioblastomas develop rapidly de novo (primary glioblastomas) or slowly through progression from low-grade or anaplastic astrocytoma (secondary glioblastomas). Recent studies have shown that these glioblastoma subtypes develop through different genetic pathways. Primary glioblastomas are characterized by EGFR amplification/overexpression, PTEN mutation, homozygous p16 deletion, and loss of heterozygosity (LOH) on entire chromosome 10, whereas secondary glioblastomas frequently contain p53 mutations and show LOH on chromosome 10q. In this study, we analyzed LOH on chromosomes 19q, 1p, and 13q, using polymorphic microsatellite markers in 17 primary glioblastomas and in 13 secondary glioblastomas that progressed from low-grade astrocytomas. LOH on chromosome 19q was frequently found in secondary glioblastomas (7 of 13, 54%) but rarely detected in primary glioblastomas (1 of 17, 6%, p = 0.0094). The common deletion was 19q13.3 (between D19S219 and D19S902). These results suggest that tumor suppressor gene(s) located on chromosome 19q are frequently involved in the progression from low-grade astrocytoma to secondary glioblastoma, but do not play a major role in the evolution of primary glioblastomas. LOH on chromosome 1p was detected in 12% of primary and 15% of secondary glioblastomas. LOH on 13q was detected in 12% of primary and in 38% of secondary glioblastomas and typically included the RB locus. Except for 1 case, LOH 13q and 19q were mutually exclusive.

Entities:  

Mesh:

Year:  2000        PMID: 10850866     DOI: 10.1093/jnen/59.6.539

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  37 in total

1.  Connexin 30 expression inhibits growth of human malignant gliomas but protects them against radiation therapy.

Authors:  Maria Artesi; Jerome Kroonen; Markus Bredel; Minh Nguyen-Khac; Manuel Deprez; Laurent Schoysman; Christophe Poulet; Arnab Chakravarti; Hyunsoo Kim; Denise Scholtens; Tatjana Seute; Bernard Rogister; Vincent Bours; Pierre A Robe
Journal:  Neuro Oncol       Date:  2014-08-25       Impact factor: 12.300

2.  MRI findings and pathological features in early-stage glioblastoma.

Authors:  Makoto Ideguchi; Koji Kajiwara; Hisaharu Goto; Kazutaka Sugimoto; Sadahiro Nomura; Eiji Ikeda; Michiyasu Suzuki
Journal:  J Neurooncol       Date:  2015-05-05       Impact factor: 4.130

3.  Differential molecular genetic analysis in glioblastoma multiforme of long- and short-term survivors: a clinical study in Chinese patients.

Authors:  Guo-Bin Zhang; Xiang-Li Cui; Da-Li Sui; Xiao-Hui Ren; Zhe Zhang; Zhong-Cheng Wang; Song Lin
Journal:  J Neurooncol       Date:  2013-03-15       Impact factor: 4.130

4.  TP53 promoter methylation in primary glioblastoma: relationship with TP53 mRNA and protein expression and mutation status.

Authors:  Dorota Jesionek-Kupnicka; Malgorzata Szybka; Beata Malachowska; Wojciech Fendler; Piotr Potemski; Sylwester Piaskowski; Dariusz Jaskolski; Wielislaw Papierz; Wieslaw Skowronski; Waldemar Och; Radzislaw Kordek; Izabela Zawlik
Journal:  DNA Cell Biol       Date:  2014-02-07       Impact factor: 3.311

5.  Correlation of histomorphologic prognostic markers and proliferative index with loss of heterozygosity 1p/19q and MGMT status in diffusely infiltrating gliomas.

Authors:  Prabal Deb; N S Mani; S M Sudumbrekar; Nitin Taneja; Seema Patrikar
Journal:  Med J Armed Forces India       Date:  2012-12-01

Review 6.  Pathology and molecular genetics of oligodendroglial tumors.

Authors:  Christian Hartmann; Wolf Mueller; Andreas von Deimling
Journal:  J Mol Med (Berl)       Date:  2004-10       Impact factor: 4.599

Review 7.  Pathology and molecular genetics of astrocytic gliomas.

Authors:  Guido Reifenberger; Vincent Peter Collins
Journal:  J Mol Med (Berl)       Date:  2004-10       Impact factor: 4.599

Review 8.  Genetic pathways to primary and secondary glioblastoma.

Authors:  Hiroko Ohgaki; Paul Kleihues
Journal:  Am J Pathol       Date:  2007-05       Impact factor: 4.307

9.  The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone.

Authors:  Remco J Molenaar; Dagmar Verbaan; Simona Lamba; Carlo Zanon; Judith W M Jeuken; Sandra H E Boots-Sprenger; Pieter Wesseling; Theo J M Hulsebos; Dirk Troost; Angela A van Tilborg; Sieger Leenstra; W Peter Vandertop; Alberto Bardelli; Cornelis J F van Noorden; Fonnet E Bleeker
Journal:  Neuro Oncol       Date:  2014-02-06       Impact factor: 12.300

Review 10.  Molecular neuropathology of gliomas.

Authors:  Markus J Riemenschneider; Guido Reifenberger
Journal:  Int J Mol Sci       Date:  2009-01-07       Impact factor: 6.208

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.